Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Partnership to develop cell lines, reagents for iPS cell research
December 2012
SHARING OPTIONS:

NEWARK, Calif.StemCells Inc. and R Biomedical have announced a partnership for the development and commercialization of a range of cell lines and reagents to support human induced pluripotent stem (iPS) cell-based research for regenerative medicine. The first product resulting from the partnership, an "ultra-primary" human fibroblast cell line from which iPS cell lines can be generated, was launched recently under the SC Proven brand. No financial terms were released.  
 
"The area of regenerative medicine is a burgeoning field both for research and as a specialized platform for pharmaceutical companies performing drug-screening campaigns. R Biomedical is extremely well positioned to provide unique iPS cell reagents, accompanying technology and culture reagents to both academic and industrial researchers in partnership with StemCells under their globally recognized and distributed SC Proven brand," said Joe Mee, R Biomedical's managing director.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.